Edwards, Martin - In: PharmacoEconomics 15 (1999) 3, pp. 269-278
Specific regulatory guidelines dictate that developing a new drug for osteoporosis will be significantly more expensive and take at least 2 years longer in comparison with other long-term therapies developed using the International Committee on Harmonisation (ICH) general guidelines. Assuming...